Paperpal Prime Logo

Anti-Cancer Drugs : Impact Factor & More

eISSN: 1473-5741pISSN: 0959-4973

Aims and Scope of Anti-Cancer Drugs

Anti-Cancer Drugs is an international medical journal, which aims to promote and encourage research on anti-cancer agents. It was first published in 1990 and it includes reports on clinical and experimental research results, from conventional cytotoxic chemotherapy to hormonal or biological response modalities. The journal has 10 issues per year and the current editor in chief is Mels Sluyser. According to the 2014 Journal Citation Reports, the journal has an impact factor of 1.784, ranking it 164th out of 211 in the category Oncology and 162nd out of 254 in the category Pharmacology & Pharmacy. Less

Key Metrics

CiteScore
5.2
H-Index
98
Impact Factor
< 5
SJR
Q3Oncology
SNIP
0.52
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Anti-Cancer Drugs

Anti-Cancer Drugs Journal Specifications

Overview
Publisher LIPPINCOTT WILLIAMS & WILKINS
Language English
Frequency Monthly
General Details
LanguageEnglish
FrequencyMonthly
Publication Start Year1990
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Anti-Cancer Drugs ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Anti-Cancer Drugs

Dauricine induces ferroptosis in neuroblastoma by inhibiting methyltransferase-like 1-mediated N7-methylguanosine methylation of solute carrier family 3 member 2.
  • 1 Sep 2026
  • Anti-cancer drugs
Isovanillin regulates gastric cancer cells apoptosis and metastasis by targeting ROS-mediated MAPK and PI3K signaling pathways.
  • 1 Sep 2026
  • Anti-cancer drugs
Clinical ethics in oncology.
  • 1 Sep 2026
  • Anti-cancer drugs
SENP3-mediated deSUMOylation stabilizes programmed death-ligand 1 to promote immune evasion in hepatocellular carcinoma.
  • 1 Sep 2026
  • Anti-cancer drugs
Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer.
  • 1 Aug 2026
  • Anti-cancer drugs
The future of cancer treatment: integrating science, technology, and global collaboration.
  • 1 Aug 2026
  • Anti-cancer drugs
Dauricine induces ferroptosis in neuroblastoma by inhibiting methyltransferase-like 1-mediated N7-methylguanosine methylation of solute carrier family 3 member 2.
  • 1 Sep 2026
  • Anti-cancer drugs
Isovanillin regulates gastric cancer cells apoptosis and metastasis by targeting ROS-mediated MAPK and PI3K signaling pathways.
  • 1 Sep 2026
  • Anti-cancer drugs
Clinical ethics in oncology.
  • 1 Sep 2026
  • Anti-cancer drugs
SENP3-mediated deSUMOylation stabilizes programmed death-ligand 1 to promote immune evasion in hepatocellular carcinoma.
  • 1 Sep 2026
  • Anti-cancer drugs
Synergistic antitumor effect between Olaparib and Chidamide by regulation of MYBL2 in lung cancer.
  • 1 Aug 2026
  • Anti-cancer drugs
The future of cancer treatment: integrating science, technology, and global collaboration.
  • 1 Aug 2026
  • Anti-cancer drugs

FAQs on Anti-Cancer Drugs